Table 1.
Group H (n=87) |
Group G (n=42) |
P-value | |
---|---|---|---|
Age (years) | 51.9±17.0 | 57.2±15.7 | 0.090 |
Male | 29 (33) | 16 (38) | 0.800 |
BSA (L/min/m2) | 1.51±0.22 | 1.57±0.19 | 0.144 |
WHO II/III/IV | 27/41/19 | 11/19/12 | 0.504 |
IPAH/CD/PPH/CHD | 38/31/4/14 | 17/12/7/6 | 0.142 |
Laboratory data | |||
BNP (pg/mL) | 238 (46–403) | 410 (69–573) | 0.084 |
UA (mg/dL) | 6.6±2.2 | 7.2±2.9 | 0.196 |
Cr (mg/dL) | 0.91±0.67 | 0.85±0.28 | 0.506 |
Echocardiography | |||
TRPG (mmHg) | 59.4±25.3 | 64.5±25.4 | 0.315 |
TAPSE (mm) | 14.2±6.2 | 16.5±5.4 | 0.307 |
Cardiac catheterization | |||
PAWP (mmHg) | 11.3±4.3 | 10±4.7 | 0.141 |
Systolic PAP (mmHg) | 73.6±30.1 | 70.3±19.6 | 0.455 |
Diastolic PAP (mmHg) | 31.0±15.7 | 27.6±9.5 | 0.140 |
Mean PAP (mmHg) | 48.2±19.6 | 44.2±11.9 | 0.153 |
PVR (Wood unit) | 7.1±6.4 | 9.5±6.4 | 0.121 |
RAP (mmHg) | 6.3±4.8 | 6.6±5.1 | 0.344 |
SvO2 (%) | 65.5±12.3 | 64.2±9.8 | 0.633 |
CO (L/min) | 4.79±1.75 | 4.38±1.5 | 0.205 |
CI (L/min/m2) | 3.12±1.21 | 2.74±0.86 | 0.082 |
Heart rate (beats/min) | 84±14 | 83±15 | 0.863 |
Data given as mean±SD, n (%) or median (range). BNP, brain natriuretic peptide; BSA, body surface area; CD, collagen disease; CHD, congenital heart disease; CI, cardiac index; CO, cardiac output; Cr, creatinine; Group G, goal-oriented sequential combination therapy; Group H, conventional empiric therapy; IPAH, idiopathic pulmonary arterial hypertension; PAH, pulmonary arterial hypertension; PAP, pulmonary arterial pressure; PAWP, pulmonary artery wedge pressure; PPH, portopulmonary hypertension; PVR, pulmonary vascular resistance; RAP, right atrial pressure; SvO2, mixed venous oxygen saturation; TAPSE, tricuspid annular plane systolic excursion: TRPG, trans regurgitation pressure gradient; UA, uric acid; WHO, World Health Organization.